 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 380315-80-0 |
| Molecular formula(MF) | C20H23N3O2S |
| Molecular Weight(MW): | 369.48 |
| Alias |
| In vitro | DMSO | 74 mg/mL (200.28 mM) |
|---|---|---|
| Water | <1 mg/mL | |
| Ethanol | <1 mg/mL | |
| In vivo | 15% Captisol | 15 mg/mL |
| Description | Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
Tenovin-1 is a p53 activator and elevates the amount of p53 protein within 2 hr of treatment. Tenovin-1 treatment does not alter p53 mRNA levels. Tenovin-1 (10μM) protects p53 from mdm2-mediated degradation with little effect on p53 synthesis. Tenovin-1 represses cell growth, and induces apoptosis in a panel of tumor cells expressing p53. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2, two important members of the sirtuin family. [1] |
||
| In vivo | Initial in vivo experiments indicated that tenovin-1 impairs the growth of BL2-derived tumor xenografts. [1] |